Literature DB >> 31949928

Survival outcomes of patients with pathological stage I gastric cancer using the competing risks survival method.

Victor Hugo Fonseca de Jesus1, Wilson Luiz da Costa2, Tiago Cordeiro Felismino1, Vinicius Fernando Calsavara3, Alessandro Landskron Diniz2, Heber Salvador de Castro Ribeiro2, André Luis de Godoy2, Igor Correia de Farias2, Felipe José Fernandez Coimbra2.   

Abstract

BACKGROUND: Patients with stage I gastric cancer are considered to have an exquisite prognosis. Nonetheless, the fact that some patients experience disease relapse highlights that a subgroup might benefit from multimodality treatment. We aimed to evaluate the survival of patients with stage I gastric cancer and look for harbingers of gastric cancer recurrence.
METHODS: We looked for patients with stage I gastric cancer treated exclusively with surgery from 1996 to 2015. The competing risks survival method was used to allow for concurrent causes of mortality. Also, we calculated subdistribution hazards (SH) to reveal factors associated with cancer recurrence and death from unrelated causes.
RESULTS: A total of 185 patients constitute the study population. Thirty-seven patients had pT2N0 tumors. Most patients (80.5%) were treated with D2 lymphadenectomy. The probability of relapse at 5 years was 3.0% and 8.6% in the study population and the pT2N0 subgroup, respectively. Among all 26 deaths, only six were related to gastric cancer. In multivariate analysis, perineural invasion (PNI) was associated with increased risk of gastric cancer recurrence.
CONCLUSIONS: The prognosis of stage I gastric cancer treated with D2 lymphadenectomy is excellent. PNI may indicate higher likelihood of recurrence. Further work in this field should account for the higher risk of death from unrelated causes. 2019 Journal of Gastrointestinal Oncology. All rights reserved.

Entities:  

Keywords:  Survival; cancer; gastric; stage I

Year:  2019        PMID: 31949928      PMCID: PMC6954996          DOI: 10.21037/jgo.2019.10.04

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  22 in total

1.  Defining a high-risk subgroup of pathological T2N0 gastric cancer by prognostic risk stratification for adjuvant therapy.

Authors:  Chunyan Du; Ye Zhou; Kai Huang; Guangfa Zhao; Hong Fu; Yingqiang Shi
Journal:  J Gastrointest Surg       Date:  2011-09-22       Impact factor: 3.452

2.  Accuracy of EUS and CT imaging in preoperative gastric cancer staging.

Authors:  Mark Fairweather; Kunal Jajoo; Nisha Sainani; Monica M Bertagnolli; Jiping Wang
Journal:  J Surg Oncol       Date:  2015-04-14       Impact factor: 3.454

3.  Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.

Authors:  Marc Ychou; Valérie Boige; Jean-Pierre Pignon; Thierry Conroy; Olivier Bouché; Gilles Lebreton; Muriel Ducourtieux; Laurent Bedenne; Jean-Michel Fabre; Bernard Saint-Aubert; Jean Genève; Philippe Lasser; Philippe Rougier
Journal:  J Clin Oncol       Date:  2011-03-28       Impact factor: 44.544

4.  The Role of Adjuvant Chemotherapy for Patients with Stage IB Gastric Cancer.

Authors:  Takahiro Toyokawa; Masaichi Ohira; Katsunobu Sakurai; Naoshi Kubo; Hiroaki Tanaka; Kazuya Muguruma; Kosei Hirakawa
Journal:  Anticancer Res       Date:  2015-07       Impact factor: 2.480

5.  Is lymphadenectomy necessary for early gastric cancer?

Authors:  S N Hochwald; M F Brennan; D S Klimstra; S Kim; M S Karpeh
Journal:  Ann Surg Oncol       Date:  1999 Oct-Nov       Impact factor: 5.344

6.  Clinicopathological analysis for recurrence of stage Ib gastric cancer (according to the second English edition of the Japanese classification of gastric carcinoma).

Authors:  Takashi Yokoyama; Kiyoshi Kamada; Yoshikazu Tsurui; Hisanori Kashizuka; Eiji Okano; Sanehito Ogawa; Shinsaku Obara; Mitsutoshi Tatsumi
Journal:  Gastric Cancer       Date:  2011-05-18       Impact factor: 7.370

7.  Early gastric cancer: prognostic factors in 223 patients.

Authors:  S Folli; M Dente; D Dell'Amore; M Gaudio; O Nanni; L Saragoni; A Vio
Journal:  Br J Surg       Date:  1995-07       Impact factor: 6.939

8.  Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.

Authors:  Shinichi Sakuramoto; Mitsuru Sasako; Toshiharu Yamaguchi; Taira Kinoshita; Masashi Fujii; Atsushi Nashimoto; Hiroshi Furukawa; Toshifusa Nakajima; Yasuo Ohashi; Hiroshi Imamura; Masayuki Higashino; Yoshitaka Yamamura; Akira Kurita; Kuniyoshi Arai
Journal:  N Engl J Med       Date:  2007-11-01       Impact factor: 91.245

9.  Validation of the 8th Edition of the AJCC TNM Staging System for Gastric Cancer using the National Cancer Database.

Authors:  Haejin In; I Solsky; B Palis; M Langdon-Embry; J Ajani; T Sano
Journal:  Ann Surg Oncol       Date:  2017-09-11       Impact factor: 5.344

10.  Prognostic factors in stage IB gastric cancer.

Authors:  Toru Aoyama; Takaki Yoshikawa; Hirohito Fujikawa; Tsutomu Hayashi; Takashi Ogata; Haruhiko Cho; Takanobu Yamada; Shinichi Hasegawa; Kazuhito Tsuchida; Norio Yukawa; Takashi Oshima; Mari S Oba; Satoshi Morita; Yasushi Rino; Munetaka Masuda
Journal:  World J Gastroenterol       Date:  2014-06-07       Impact factor: 5.742

View more
  2 in total

1.  The Clinicopathological Features and Overall Survival of Patients With Gastric Neuroendocrine Carcinoma.

Authors:  Bin Xu; Yuxin Chu; Qinyong Hu; Qibin Song
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

2.  Candidate genes for predicting the survival of patients with gastric cancer: a study based on The Cancer Genome Atlas (TCGA) database.

Authors:  Xiqiao Liu; Liying Gao; Dongqiong Ni; Chengao Ma; Yuping Lu; Xuan Huang
Journal:  Transl Cancer Res       Date:  2020-04       Impact factor: 1.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.